Richard A. Lewis, MD

What you missed at Glaucoma 360 this year
What you missed at Glaucoma 360 this yearSee the highlights and program overview from the Glaucoma Research Foundation's 2017 Glaucoma 360!
Rocket 2 meets safety endpoints for netarsudilNetarsudil ophthalmic solution 0.02% q.d. maintained consistent IOP-lowering efficacy through 12 months for the Rocket 2 trial.
A bullish view: Navigating beyond glaucoma company mistakesCompanies specializing in glaucoma products can make billions of dollars, but only if they can find a path through a minefield of scientific, regulatory, and marketing hazards, according to Richard A. Lewis, MD.
Sustained-release bimatoprost implant addresses challenges of adherencePhase I/II interim data for a bimatoprost sustained-release implant show the device has favorable safety and efficacy and may address the problem of patient nonadherence.
ROCK inhibitors show promise in glaucoma treatmentA novel class of drugs ‒ rho-kinase, or ROCK inhibitors ‒ appears to lower IOP by relaxing the trabecular meshwork.
Fixed-dose combination glaucoma drug provides easy, safe IOP controlOnce-daily dosing of one drop of Roclatan (Aerie Pharmaceuticals, Inc.), containing a fixed-dose combination of latanoprost and a rho kinase inhibitor and norepinephrine transport inhibitor, was clinically and statistically superior to administration of its individual components for controlling IOP in open-angle glaucoma or ocular hypertension.